scholarly journals Heparin Neutralization with Methylene Blue, Hexadimethrine, or Vancomycin After Cardiopulmonary Bypass

1996 ◽  
Vol 83 (2) ◽  
pp. 223-227 ◽  
Author(s):  
Mutsuhito Kikura ◽  
Mi K. Lee ◽  
Jerrold H. Levy
1996 ◽  
Vol 10 (4) ◽  
pp. 474-476 ◽  
Author(s):  
Samuel Metz ◽  
Jan C. Horrow ◽  
Inder P. Goel ◽  
M.L.R. Kuretu ◽  
Collette Bellwoar

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Paul Harding ◽  
Thomas Nicholas ◽  
Cale Kassel

The use of methylene blue for vasoplegia in cardiac cases with cardiopulmonary bypass, septic shock, and acute liver failure is well documented. Use of MB for liver transplantation has been largely limited to case reports. We describe three separate liver transplantation patients with significant hypotension following reperfusion. Administration of methylene blue to each patient resulted in a significant decrease in vasopressor medication and two patients weaned completely. We argue that the use of MB should be considered as a treatment option for refractory hypotension.


2017 ◽  
Vol 20 (5) ◽  
pp. 234 ◽  
Author(s):  
Alexander T. Booth ◽  
Patrick D. Melmer ◽  
Benjamin Tribble ◽  
J. Hunter Mehaffey ◽  
Curt Tribble

Vasoplegic syndrome is a form of vasodilatory shock that occurs frequently in patients who undergo cardiac surgery requiring cardiopulmonary bypass (CBP). Treatment often demands high doses of vasopressors over sustained periods for hypotension that can be refractory to standard vasoactive medications. Furthermore, the development of vasoplegia greatly contributes to morbidity and mortality following cardiac surgery. Methylene blue (MB) has become a popular therapy for cardiac vasoplegia despite a paucity of prospective data to direct its use. Therefore, the aim of this study was to review available data regarding mechanisms, dosing strategies, and side effects of MB, with a focus on its applications for vasoplegia in cardiac surgery.


1997 ◽  
Vol 78 (02) ◽  
pp. 820-826 ◽  
Author(s):  
Bruce D Spiess ◽  
Michael H Wall ◽  
Bruce S Gillies ◽  
Jane C K Fitch ◽  
Louise O Soltow ◽  
...  

SummaryThromboelastography (TEG) has been used after cardiopulmonary bypass (CPB) to diagnose excessive postoperative hemorrhage. Conventional TEG during CPB is not possible due to the sensitivity of the TEG to even small amounts of heparin, which produces a nondiagnostic tracing. The purpose of this study was to compare heparin neutralization using heparinase or protamine in TEG blood samples obtained during CPB. TEG testing was performed on 48 patients before, during and after CPB. Tissue plasminogen activator activity and antigen were measured on a subset of 32 patients. We found: 1) heparinase neutralized at least 10 IU/ml heparin while 1.6 ug/ml protamine neutralized up to 7 IU/ml heparin, 2) in samples with complete heparin neutralization by both methods, there was no significant difference in the R values, 3) while there was good correlation for other TEG parameters between heparinase and protamine treated samples, heparinase treatment produced shorter K values and higher angle, MA and A60, 4) while fibrinolysis was detected using both methods, heparinase treatment suppressed fibrinolysis in the TEG in both samples from patients and after in vitro addition of tissue plasminogen activator, 5) TEG was not a sensitive indicator of t-PA activity, detecting only 21% of samples with increased t-PA activity during bypass, and 5) heparinase was at least 100 times more expensive than protamine. We conclude that while both heparinase and protamine can be used to neutralize heparin in TEG samples obtained during CPB, protamine neutralization is more sensitive to fibrinolysis and less expensive, but the protamine dose must be carefully selected to match the heparin level used at individual institutions.


2015 ◽  
Vol 5 (8) ◽  
pp. 127-130 ◽  
Author(s):  
Michelle Carley ◽  
Jacob Schaff ◽  
Terrance Lai ◽  
Jeremy Poppers

Sign in / Sign up

Export Citation Format

Share Document